The therapeutic effects of HDAC inhibitors are based on their ability to affect the transcription of various genes; in particular, anti-tumor effects can be attributed to the transcriptional reactivation of silent tumor suppressor genes and the transcriptional repression of proto-oncogenes (Boumber and Issa, 2011). This evidence concerns the gene HDAC9 and neoplasm.